Surface-Modified Silica Hydrogels for the Programmable Release of Bisphosphonate Anti-Osteoporosis Drugs: The Case of Etidronate
Bisphosphonate drugs constitute the primary treatment for bone diseases such as Paget’s disease and osteoporosis. Despite their effectiveness, they also exhibit severe drawbacks, such as rapid excretion and limited oral bioavailability. High doses are usually administered to counterbalance these dra...
Main Authors: | Fanouria-Eirini G. Alatzoglou, Maria Vassaki, Kalliopi Nirgianaki, Eleftherios Tripodianos, Petri Turhanen, Konstantinos D. Demadis, Konstantinos E. Papathanasiou |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Materials |
Subjects: | |
Online Access: | https://www.mdpi.com/1996-1944/16/9/3379 |
Similar Items
-
Calcium and Strontium Coordination Polymers as Controlled Delivery Systems of the Anti-Osteoporosis Drug Risedronate and the Augmenting Effect of Solubilizers
by: Maria Vassaki, et al.
Published: (2021-12-01) -
Drug-Inclusive Inorganic–Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate
by: Maria Vassaki, et al.
Published: (2022-09-01) -
Preparation of mixed trialkyl alkylcarbonate derivatives of etidronic acid via an unusual route
by: Petri A. Turhanen, et al.
Published: (2012-11-01) -
6-Bromo-1-hydroxyhexane-1,1-bisphosphonic Acid Monosodium Salt
by: Petri A. Turhanen
Published: (2022-10-01) -
Calcium Phosphate/Etidronate Disodium Biocement: Etidronate, Retarder or Accelerator
by: Nasim Nosoudi, et al.
Published: (2014-03-01)